Zerbaxa® (ceftolozane/tazobactam) – New indication
June 3, 2019 - The FDA announced the approval of Merck’s Zerbaxa (ceftolozane/tazobactam), for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), caused by the following susceptible gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Serratia marcescens.
Top